We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    NCT02581059 | Recruiting Studies
Previous Study | Return to List | Next Study

Efficacy of Ginseng for Patients on Regorafenib

This study is currently recruiting participants.
Verified September 2017 by Rodwige J. Desnoyers, Hoosier Cancer Research Network
Sponsor:
ClinicalTrials.gov Identifier:
NCT02581059
First Posted: October 20, 2015
Last Update Posted: September 14, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
Collaborators:
Bayer
Hoosier Cancer Research Network
Information provided by (Responsible Party):
Rodwige J. Desnoyers, Hoosier Cancer Research Network
  Purpose
This is a randomized, multi-center phase II study of ginseng in colorectal cancer patients treated with regorafenib to determine if ginseng will reduce fatigue in this patient population and improve adherence to regorafenib. Ninety (90) subjects will be enrolled and randomized using a 2:1 allocation, with 60 subjects enrolled in the regorafenib + ginseng group and 30 enrolled in the regorafenib + no ginseng group.

Condition Intervention Phase
Colorectal Cancer Palliative Medicine Supportive Care Drug: Regorafenib Dietary Supplement: Ginseng Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Randomized Phase II Trial to Evaluate the Efficacy of Supportive Therapy With Ginseng for Patients on Treatment With Regorafenib

Resource links provided by NLM:


Further study details as provided by Rodwige J. Desnoyers, Hoosier Cancer Research Network:

Primary Outcome Measures:
  • Subject Fatigue Assessment [ Time Frame: From date of first dose until end of cycle 2 (8 weeks) ]
    Fatigue will be assessed for subjects on each arm using the Multidimensional Fatigue Symptom Inventory-Short Form (MFSI-SF) and Patient-Reported Outcomes Measurement Information System (PROMIS)


Secondary Outcome Measures:
  • Subject Compliance [ Time Frame: From date of first dose until end of cycle 2 (8 weeks) ]
    Pill counts will be used to assess adherence to regorafenib for subjects on each arm

  • Characterize Adverse Events (AE) [ Time Frame: From date of first dose until end of cycle 2 (8 weeks) ]
    Toxicity assessed using Common Terminology Criteria for Adverse Events v4.0 (CTCAE v4.0) criteria

  • Subject Retention [ Time Frame: From date of first dose until end of cycle 2 (8 weeks) ]
    Retention will be determined by the proportion of subjects on each arm who complete the study.

  • Evaluate Response Rate (RR) [ Time Frame: 18 months ]
    the proportion of all subject with confirmed PR or CR according to RECIST v.1.1, from the start of treatment until disease progression/recurrence

  • Evaluate Overall Survival (OS) [ Time Frame: 18 months ]
    date of randomization to date of death from any cause


Estimated Enrollment: 90
Study Start Date: April 2016
Estimated Study Completion Date: December 2018
Estimated Primary Completion Date: December 2017 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Regorafenib + Ginseng
Regorafenib will be administered 160 mg once daily for the first 21 days of each 28-day cycle. Subjects will receive 1,000 mg ginseng orally twice daily every day for 4 weeks (2 cycles).
Drug: Regorafenib
All subjects will receive regorafenib 160 mg orally once daily for the first 21 days of each 28-day cycle for 2 cycles.
Other Name: Stivarga
Dietary Supplement: Ginseng
Subjects randomized to ginseng will receive 1,000 mg orally twice every day of each 28-day cycle for 2 cycles.
Other Name: Panax quinquefolius
Active Comparator: Regorafenib Only
Regorafenib will be administered 160 mg once daily for the first 21 days of each 28-day cycle for 2 cycles.
Drug: Regorafenib
All subjects will receive regorafenib 160 mg orally once daily for the first 21 days of each 28-day cycle for 2 cycles.
Other Name: Stivarga

Detailed Description:

OUTLINE: This is a multi-center study.

INVESTIGATIONAL TREATMENT:

Regorafenib will be administered 160 mg orally once daily for the first 21 days of each 28-day cycle. Subjects that randomize to receive ginseng will take 1,000 mg orally twice daily every day for 4 weeks (2 cycles). Subjects that randomize to NOT receive ginseng will not be given ginseng. Subjects will be instructed to take regorafenib with a low-fat meal.

Subjects will undergo fatigue assessments, using the MFSI-SF instrument and PROMIS. Subjects will have a pill count C2D1 and at the end of treatment visit. Subjects will have the re-staging scan (CT of chest/abdomen/pelvis) at the end of Cycle 2/ week 8 (±5).

Adequate bone marrow, liver and renal function assessed by the following laboratory values obtained within 7 days prior to registration for protocol therapy:

Hematopoietic:

  • Absolute neutrophil count (ANC) count > 1,500/mm^3
  • Hemoglobin (Hgb) > 9g/dL
  • Platelet count > 100,000/mm^3

Renal:

  • Serum creatinine ≤ 1.5 × the upper limit of normal (ULN)

Hepatic:

  • Total bilirubin ≤ 1.5 × the upper limit of normal (ULN).
  • Alanine aminotransferase (ALT) and aspartate amino-transferase (AST) ≤ 2.5 x ULN (≤ 5 × ULN for subjects with liver involvement of their cancer)
  • Alkaline phosphatase (ALP) limit ≤ 2.5 × ULN (≤ 5 × ULN for subjects with liver involvement of their cancer)

Coagulation:

  • International normalized ratio (INR)/Partial thromboplastin time (PTT) ≤ 1.5 × ULN. NOTE: Subjects who are prophylactically treated with an agent such as warfarin or heparin will be allowed to participate if no prior evidence of underlying abnormality in coagulation parameters exists. Close monitoring of at least weekly evaluations will be performed until INR/PTT is stable, based on a measurement that is pre-dose as defined by the local standard of care. Warfarin does should not exceed 1 mg.
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Subjects must be able to understand and be willing to sign the written informed consent and Health Insurance Portability and Accountability Act of 1996 (HIPAA) authorization for release of personal health information. A signed informed consent form (ICF) must be appropriately obtained prior to the conduct of any trial-specific procedure. NOTE: HIPAA authorization may be included in the informed consent or obtained separately.
  • Age ≥ 18 years at the time of consent.
  • Life expectancy of at least 12 weeks (3 months) as determined by the treating physician.
  • Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1 within 28 days prior to registration.
  • Histological or pathologically confirmed stage IV adenocarcinoma of the colon.
  • Women of childbearing potential must have a negative serum pregnancy test performed within 7 days prior to the start of study drug. Post-menopausal women (defined as no menses for at least 1 year) and surgically sterilized women are not required to undergo a pregnancy test.
  • Subjects (men and women) of childbearing potential must agree to use adequate contraception beginning at the signing of the ICF until at least 2 months after the last dose of study drug. The definition of adequate contraception will be based on the judgment of the treating physician or a designated associate. NOTE: Examples of adequate contraception may include but are not limited to a combination of any two of the following: use of oral, injected or implanted hormonal methods of contraception; placement of an intrauterine device (IUD) or intrauterine system (IUS); barrier methods of contraception (condom or occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/ film/cream/vaginal suppository); total abstinence; male/female sterilization
  • All subjects must have radiographically assessable disease per RECIST v1.1 obtained by imaging within 28 days prior to registration.
  • Must be able to swallow and retain oral medication.
  • Subject must be deemed a suitable candidate for regorafenib as per their treating physician.

Exclusion Criteria:

  • Subject should not be receiving any agent for fatigue including steroids, megace or opioids. NOTE: Subjects who have a contrast-induced allergy are allowed to receive steroids for their scans.
  • Radiotherapy within 2 weeks prior to study registration. Subjects must have recovered from all therapy-related toxicities.
  • Prior treatment with regorafenib.
  • Previous assignment to treatment during this study. Subjects permanently withdrawn from study participation will not be allowed to re-enter study.
  • Congestive heart failure > New York Heart Association (NYHA) class 2: unstable angina (angina symptoms at rest), new-onset angina (begun within the last 3 months), myocardial infarction less than 6 months before study registration; cardiac arrhythmias requiring anti-arrhythmic therapy (beta blockers or digoxin are permitted); uncontrolled hypertension (systolic blood pressure > 150 mmHg or diastolic pressure > 90 mmHg despite optimal medical management).
  • Evidence or history of bleeding diathesis or coagulopathy.
  • Any hemorrhage or bleeding event ≥ NCI CTCAE Grade 3 within 4 weeks prior to study registration.
  • Subjects with thrombotic, embolic, venous, or arterial events, such as cerebrovascular accident (including transient ischemic attacks), deep vein thrombosis or pulmonary embolism within 6 months of study registration.
  • Previous or concurrent cancer that is distinct in primary site or histology from colorectal cancer within 3 years prior to randomization EXCEPT for curatively treated cervical cancer in situ, non-melanoma skin cancer and superficial bladder tumors [Ta (Non-invasive tumor), Tis (Carcinoma in situ) and T1 (Tumor invades lamina propria)].
  • Subjects with pheochromocytoma.
  • Known history of human immunodeficiency virus (HIV) infection or current chronic or active hepatitis B or C infection requiring treatment with antiviral therapy.
  • Ongoing infection > Grade 2 NCI-CTCAE v4.0.
  • Metastatic brain or meningeal tumors (symptomatic or asymptomatic).
  • Major surgical procedure or significant traumatic injury, as defined by the site investigator, within 28 days before study registration.
  • Renal failure requiring hemo- or peritoneal dialysis
  • Dehydration Grade > 2 NCI CTCAE v4 within 7 days prior to registration.
  • Subjects with seizure disorder currently requiring medication.
  • Persistent proteinuria ≥ Grade 3 NCI CTCAE v4.0 as defined as > 3.5 g/24 hours, measured by urine protein: creatinine ratio on a random urine sample.
  • Interstitial lung disease with ongoing signs and symptoms at the time of study registration.
  • Pleural effusion or ascites that causes respiratory compromise (≥ NCI CTCAE version 4.0 Grade 2 dyspnea).
  • History of organ allograft (including corneal transplant).
  • Known or suspected allergy or hypersensitivity to any of the study drugs, study drug classes, or excipients of the formulations given during the course of this trial.
  • Any malabsorption condition which, in the opinion of the treating physician, will affect the absorption of any of the agents used in this study.
  • Women who are pregnant or breast-feeding.
  • Any condition, which, in the site investigator's opinion, makes the subject unsuitable for trial participation.
  • Substance abuse, medical, psychological, or social conditions that may interfere with the subject's participation in the study or evaluation of the study results.
  • Treatment with any investigational agent within 28 days prior to registration.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02581059


Contacts
Contact: Rodwige J. Desnoyers, M.D. 336-716-7209 rdesnoye@wakehealth.edu
Contact: Donna Sullivan 317.634.5842 ext 40 dsullivan@hoosiercancer.org

Locations
United States, Indiana
Indiana Univeristy Melvin and Bren Simon Cancer Center Recruiting
Indianapolis, Indiana, United States, 46202
Contact: La Trice Vaughn, RN    317-278-3730    lgvaughn@iupui.edu   
Principal Investigator: Amikar Sehdev, MD, MPH         
IU Health Central Indiana Cancer Centers Recruiting
Indianapolis, Indiana, United States, 46219
Contact: Cara Ellis, RN    317-678-2738    cellis6@iuhealth.org   
Principal Investigator: Andrew Greenspan, MD         
United States, New Jersey
Altantic Health System Recruiting
Morristown, New Jersey, United States, 07960
Contact: Christie Rice    973-971-5235    Christie.Rice@atlantichealth.org   
Principal Investigator: Angela Alistar, MD         
United States, North Carolina
Comprehensive Cancer Center at Wake Forest Baptist Recruiting
Winston-Salem, North Carolina, United States, 27157
Contact: Rodwige J. Desnoyers, M.D.    336-716-7209    rdesnoye@wakehealth.edu   
Contact: Jessica Leach    336-713-6908    jleach@wakehealth.edu   
United States, Pennsylvania
Gettysburg Cancer Center Recruiting
Gettysburg, Pennsylvania, United States, 17325
Contact: Vanessa Hardman    717-334-4033    vhardman@gettysburgoncology.com   
Principal Investigator: Tina Khair, DO         
Sponsors and Collaborators
Rodwige J. Desnoyers
Bayer
Hoosier Cancer Research Network
Investigators
Study Chair: Rodwige J. Desnoyers, M.D. Hoosier Cancer Research Network
  More Information

Additional Information:
Responsible Party: Rodwige J. Desnoyers, Sponsor-Investigator, Hoosier Cancer Research Network
ClinicalTrials.gov Identifier: NCT02581059     History of Changes
Other Study ID Numbers: HCRN GI14-191
First Submitted: October 16, 2015
First Posted: October 20, 2015
Last Update Posted: September 14, 2017
Last Verified: September 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Keywords provided by Rodwige J. Desnoyers, Hoosier Cancer Research Network:
Regorafenib
American Ginseng
Fatigue

Additional relevant MeSH terms:
Colorectal Neoplasms
Intestinal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Neoplasms
Digestive System Diseases
Gastrointestinal Diseases
Colonic Diseases
Intestinal Diseases
Rectal Diseases